Life Sciences

Predictive Modeling for Pharma Marketers: The Personalization Prescription

There’s massive opportunity in the $1,200 billion world of pharmaceutical marketing, and substantive shifts are underway as big data increases scope and narrows focus. Pharma marketers now face the challenge of combining high-level, abstract knowledge with personalized recommendations tailored to patient and health care provider (HCP) needs. Existing sales strategies and current categorization methods are […]

Continue reading

People are at the Heart of Patient-Level Clinical Data

Pharmaceutical companies recognize the value of patient-level clinical data, and thanks to a combination of evolving technology and emerging legislation, there’s more data available than ever: Over 86 percent of physicians now use some form of electronic medical record (EMR) or electronic health record (EHR) system, according to the CDC. But the sheer influx of […]

Continue reading

Learn more about IBM


IBM Solutions and Services for Healthcare

Transform your organization’s value with access to new and unprecedented amounts of data - across populations and at the level of the individual - for deeper insight, personalization and earlier interventions.

Join the Conversation


Pharma Engagement Strategy with Integrated Delivery Networks (IDNs)

Engaging Integrated Delivery Networks (IDNs) effectively requires a reconsideration of the traditional commercial model. The traditional commercial model based on reach & frequency and patient metrics is inadequate. Embracing a more account-centric model is necessary to adapt to the growing influence of IDNs. Some examples of approaches emerging throughout the industry are: Hybrid Sales Forces […]

Continue reading

Pharma Engagement Strategy: Embedding in Clinical Pathways

Clinical pathways are formalized processes of care designed to reduce treatment variability. They can also be referred to as integrated care pathways (ICPs) or care maps. While every medical case is unique, payers and providers are attempting to standardize treatment since unnecessary variation is a major source of growing costs. These formalized processes may take […]

Continue reading

How life sciences industry is using advanced technologies to transform drug safety?

Protecting the patient’s well-being is a key responsibility for the life sciences industries. Companies must act quickly to evaluate, assess and report adverse events, and identify new and serious safety signals. This process, pharmacovigilance, is heavily dependent on human-beings.  With the volume of adverse events increasing annually by 10%;  additional channels (such as electronic medical […]

Continue reading

Using Watson to Accelerate Drug Discovery

IBM Watson Health aims to transform the drug development process for life sciences – from research to commercialization. IBM Watson for Drug Discovery helps accelerate breakthroughs by enabling researchers to quickly analyze, identify, and prioritize new therapeutic targets and drug combinations for future study. Imagine if you could:  Access structured and unstructured data from disparate […]

Continue reading

Better Engage with Patients and Partners Using Watson Health Core and the IBM Cloud

IBM Watson Health Core IBM Watson Health Core is a health data platform specifically designed to meet the needs of life science leaders, medical device companies, researchers and others in this complex, ever-evolving marketplace. Watson Health Core provides more than basic cloud infrastructure: It helps accelerate the consistency and velocity of innovation with a HIPAA-enabled, […]

Continue reading

A C-Suite Perspective on Increasing the Velocity of Successful Transformation for Global Industries: An interview with Vivek Ramaswamy, CEO of Roivant Sciences and CEO of Axovant Sciences

Preface: While many corporate transformations are rightfully investing in new initiatives to grow top-line revenue, are there other strategic options that companies could pursue with assets that have been lying dormant? This Q&A is part of a series inspired by Fortune’s Most Admired Company rankings.[1] The process includes interviewing executives and professors for their insights […]

Continue reading

A C-Suite Perspective on Increasing the Velocity of Successful Transformation for Global Industries: An interview with Fred Hassan, Partner & Managing Director of Warburg Pincus

Preface: A turnaround expert with a unique track record in the intensely competitive pharmaceutical industry, Fred Hassan has led successful turnarounds at a number of multinational firms. His leadership approach is described in “Reinvent, A Leader’s Playbook for Serial Success”, a book that has received acclaim from healthcare CEOs as well as from industry leaders […]

Continue reading

Innovating in the age of ecosystems

Persistent disruptive forces in life sciences are threatening traditional business models over the medium to long term. New technologies are driving radical disruption, value chains are fragmenting and industries are converging. While high rates of return and strong performance may have masked these forces in the past, today they need to be recognized and addressed […]

Continue reading

A C-Suite Perspective on Increasing the Velocity of Successful Transformation for the Pharmaceutical Industry: An interview with Dr. Linda A. Hill, Professor at the Harvard Business School

Preface: As the pharmaceutical industry continues to make progress at transformation, what ground-breaking strategies could help accelerate its success? With Apple Computer’s recent attainment as the top ranked Fortune Most Admired Company* for an unprecedented eight consecutive years as an inspirational guidepost, this Q&A with Dr. Linda A. Hill explains how the industry could potentially […]

Continue reading

A C-Suite Perspective on Increasing the Velocity of Successful Transformation for the Pharmaceutical Industry: An interview with Dr. David-Alexandre Gros, Executive Vice President, Chief Strategy Officer at Sanofi

Preface: As the pharmaceutical industry continues to make progress against its transformation, what ground-breaking strategies are the firms deploying? Similar to how Apple Computer recently chalked up the top ranking of Fortune’s Most Admired Company* for an unprecedented eight consecutive years; this Q&A with Dr. David-Alexandre Gros, Executive Vice President and Chief Strategy Officer of […]

Continue reading